Wei Qian, Li Ze, Feng Honglei, Ren Li
Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Cancer Manag Res. 2021 May 7;13:3675-3683. doi: 10.2147/CMAR.S304719. eCollection 2021.
Pancreatic cancer (PC) is one of the worst prognoses amongst all malignant diseases. It is therefore of great significance to identify biomarkers with predictive clinical value for the prognosis and recurrence of PC.
In our study, enzyme-linked immunosorbent assays (ELISA) were used to detect the expression of Exo-EphA2 in the serum of PC patients and controls. Kaplan-Meier curve and Cox regression analyses were used to evaluate the prognostic value of Exo-EphA2 expression in patients with primary and recurrent PC.
The level of serum Exo-EphA2 was significantly higher in the PC group when compared to that of the control group. High expression of Exo-EphA2 in PC was associated with shorter overall survival (OS) and proved to be a significant negative prognostic factor in the multivariate analysis (HR = 1.04, 95% CI: 1.00-1.09, P <0.001). Additionally, we found that the level of serum Exo-EphA2 in recurrent PC patients (first recurrence < 12 months) was positively correlated with the level of Exo-EphA2 at primary diagnosis. Multivariate analysis showed that a high expression of Exo-EphA2 in recurrent PC was associated with shorter recurrence-free survival (RFS) (HR = 1.41, 95% CI: 1.10-1.70, P < 0.001).
High expression of serum Exo-EphA2 represents a novel biomarker for a poor prognosis in PC patients.
胰腺癌（PC）是所有恶性疾病中预后最差的疾病之一。因此，识别具有预测临床价值的生物标志物对于胰腺癌的预后和复发具有重要意义。
在我们的研究中，采用酶联免疫吸附测定（ELISA）检测胰腺癌患者和对照组血清中Exo-EphA2的表达。采用Kaplan-Meier曲线和Cox回归分析评估Exo-EphA2表达在原发性和复发性胰腺癌患者中的预后价值。
与对照组相比，胰腺癌组血清Exo-EphA2水平显著升高。胰腺癌中Exo-EphA2的高表达与总生存期（OS）缩短相关，并且在多变量分析中被证明是一个显著的负性预后因素（HR = 1.04，95%CI：1.00-1.09，P <0.001）。此外，我们发现复发性胰腺癌患者（首次复发<12个月）血清Exo-EphA2水平与初次诊断时Exo-EphA2水平呈正相关。多变量分析显示，复发性胰腺癌中Exo-EphA2的高表达与无复发生存期（RFS）缩短相关（HR = 1.41，95%CI：1.10-1.70，P <0.001）。
血清Exo-EphA2的高表达代表了胰腺癌患者预后不良的一种新型生物标志物。
